Evidence map›Paper›PMID 39608864›Full record

ArticleRMD open2024

Relationship between high-resolution computed tomography quantitative imaging analysis and physiological and clinical features in antisynthetase syndrome-related interstitial lung disease.

Sangmee Sharon Bae, Fereidoun Abtin, Grace Kim, Daniela Markovic, Cato Chan, Siamak Moghadam-Kia, Chester V Oddis, Daniel Sullivan, Galina Marder, Swamy Venuturupalli and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03215927 (A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03215927 phase2completednot on this map

A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome

TypeinterventionalSponsorRohit Aggarwal, MDRan2018 to 2023Enrolled20ConditionsMyositis, Interstitial Lung DiseaseArmsAbatacept, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sangmee Sharon BaeDivision of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-7216-7219
Fereidoun AbtinDepartment of Radiology, University of California Los Angeles, Los Angeles, California, USA.
Grace KimDepartment of Radiology, University of California Los Angeles, Los Angeles, California, USA.
Daniela MarkovicDepartment of Medicine Statistics Core, University of California Los Angeles, Los Angeles, California, USA.
Cato ChanDepartment of Radiology, University of California Los Angeles, Los Angeles, California, USA.
Siamak Moghadam-KiaDepartment of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Chester V OddisDepartment of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Daniel SullivanDepartment of Medicine, Division of Pulmonology and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Galina MarderDepartment of Rheumatology, Northwell Health, New Hyde Park, New York, USA.
Swamy VenuturupalliDepartment of Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Paul F DellaripaDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Tracy J DoyleDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Gary Matt HunninghakeDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Jeremy FalkDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Christina Charles-SchoemanDivision of Rheumatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-1768-7019
Donald P TashkinDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Jonathan GoldinDepartment of Radiology, University of California Los Angeles, Los Angeles, California, USA.
Rohit AggarwalDepartment of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA aggarwalr@upmc.edu.ORCID 0000-0001-7531-8038

Funding

Altered High-Density Lipoprotein function in Patients with Idiopathic Inflammatory MyopathiesK23AR081423 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sangmee Bae · 2023 to 2026
$728k
NIAMS NIH HHS K23 AR081423
6 · The paper itself

Abstract

objectivesTo explore the association between the extent of CT abnormalities by quantitative imaging analysis (QIA) and clinical/physiological disease parameters in patients with antisynthetase syndrome associated interstitial lung disease (ARS-ILD).

methodsWe analysed 20 patients with antisynthetase antibodies and active ILD enrolled in the Abatacept in Myositis-Associated Interstitial Lung Disease study. High-resolution chest CT was obtained at weeks 0, 24 and 48 and QIA scored the extent of ground glass (quantitative score for ground glass), fibrosis (quantitative score for lung fibrosis, QLF) and total ILD (quantitative ILD, QILD). Mixed-effects models estimated longitudinal QIA scores over time. Associations between QIA scores with clinical/physiological parameters were analysed longitudinally using repeated-measures mixed-effects models.

resultsPatients were median age 57 years, 55% males and 85% white. Higher (worse) baseline QIA scores correlated with lower baseline forced vital capacity (FVC) and diffusing capacity adjusted for haemoglobin (DLCO). Longitudinal QIA trajectories trended towards improving scores during the trial, and patients on O

conclusionsLongitudinal QIA scores associate with lung physiology, patient perception of respiratory status, overall disease activity and quality of life over time in ARS-ILD. QIA may allow reproducible monitoring of disease progression and response to therapy over time. TRIAL REGISTRATION NUMBER: NCT03215927.

Indexed as

Lung Diseases, InterstitialMyositisTomography, X-Ray ComputedAdultAgedFemaleHumansLungMaleMiddle AgedRespiratory Function TestsVital CapacityDermatomyositisOutcome Assessment, Health CarePolymyositisPulmonary Fibrosis

Identifiers

PMID39608864
PMCPMC11603737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.